首页>
外国专利>
monomeric and dimeric forms of adiponectin receptor fragments and methods of use
monomeric and dimeric forms of adiponectin receptor fragments and methods of use
展开▼
机译:脂联素受体片段的单体和二聚体形式及其使用方法
展开▼
页面导航
摘要
著录项
相似文献
摘要
A method of determining the progression, initiation, or efficacy of diabetes treatment characterized by an adipocyte imbalance in a patient, comprising: determining a level of a peptide in a sample of biological fluid obtained from said patient; wherein said peptide is selected from the group consisting of: a first heterodimer comprising a first grouper unit and a second grouper unit, wherein said first grouper unit has at least approximately 90% identity with SEQ ID NO: 5 and wherein said second mer unit has at least about 90% identity with SEQ ID NO: 6, and wherein said first mer unit and said second mer unit are joined via a disulfide bond; a first homodimer comprising a first grouper unit and a second grouper unit, wherein said first grouper unit has at least approximately 90% identity with SEQ ID NO: 6 and wherein said second grouper unit is at least approximately 90% identity with SEQ ID NO: 6, and wherein said first mer unit and said second mer unit are joined via a disulfide bond; a second heterodimer comprising a first grouper unit and a second grouper unit, wherein said first grouper unit has at least approximately 90% identity with SEQ ID NO: 1 and wherein said second grouper unit is at least approximately 90% identity with SEQ ID NO: 6, and wherein said first mer unit and said second mer unit are linked through a disulfide bond; a third heterodimer comprising a first grouper unit and a second grouper unit, wherein said first grouper unit has at least approximately 90% identity with SEQ ID NO: 2 and wherein said second grouper unit is at least approximately 90% identity with SEQ ID NO: 6, and wherein said first mer unit and said second mer unit are linked through a disulfide bond; a dimer of said first heterodimer; a dimer of said first homodimer; a dimer of said second heterodimer; a dimer of said third heterodimer; and correlating the level of said selected peptide with said progression of onset of or efficacy of diabetes treatment.
展开▼
机译:一种确定以患者中的脂肪细胞失衡为特征的糖尿病治疗的进展,开始或功效的方法,包括:确定从所述患者获得的生物液样品中的肽水平;其中所述肽选自由以下组成的组:包含第一石斑鱼单元和第二石斑鱼单元的第一异二聚体,其中所述第一石斑鱼单元与SEQ ID NO:5具有至少约90%的同一性,并且其中所述第二mer单元具有与SEQ ID NO:6具有至少约90%的同一性,并且其中所述第一mer单元和所述第二mer单元通过二硫键连接;第一同源二聚体,其包括第一石斑鱼单元和第二石斑鱼单元,其中所述第一石斑鱼单元与SEQ ID NO:6具有至少约90%的同一性,并且其中所述第二石斑鱼单元与SEQ ID NO:6具有至少约90%的同一性: 6,其中所述第一单体单元和所述第二单体单元通过二硫键连接;第二异二聚体,其包括第一石斑鱼单元和第二石斑鱼单元,其中所述第一石斑鱼单元与SEQ ID NO:1具有至少约90%的同一性,并且其中所述第二石斑鱼单元与SEQ ID NO:1具有至少约90%的同一性: 6,其中所述第一单体单元和所述第二单体单元通过二硫键连接;第三异二聚体,其包含第一石斑鱼单元和第二石斑鱼单元,其中所述第一石斑鱼单元与SEQ ID NO:2具有至少约90%的同一性,并且其中所述第二石斑鱼单元与SEQ ID NO:2具有至少约90%的同一性: 6,其中所述第一单体单元和所述第二单体单元通过二硫键连接;所述第一异二聚体的二聚体;所述第一同源二聚体的二聚体;所述第二异二聚体的二聚体;所述第三异二聚体的二聚体;使所述选择的肽的水平与所述糖尿病治疗的发作或疗效相关。
展开▼